Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.Annals of Surgical Oncology|August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.Medrxiv : the Preprint Server for Health Sciences|September 5, 2025
Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast CancerFrederick M Howard, James Dolezal, Hanna Hieromnimon, et al.Annals of Surgical Oncology|July 24, 2025
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.Journal of the National Cancer Institute. Monographs|November 2, 2011
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010)Alfredo Berruti, Daniele Generali, Manfred Kaufmann, et al.JCO Precision Oncology|April 10, 2025
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study AnalysisEric Hahnen, Jan Hauke, Karen Gelmon, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 23, 2026
Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial CohortCarsten Denkert, Sivaramakrishna Rachakonda, Anika Pehl, et al.Journal of the National Cancer Institute|June 22, 2026
Comparative 10-year performance of mammography artificial intelligence, polygenic, and clinical breast cancer risk models in the Kaiser Permanente Research BankVignesh A Arasu, Tejomay Gadgil, Joseph H Rothstein, et al.Pageof 5